Enhancing the diversity of clinical trial populations is critical to achieving equity in healthcare and improving health outcomes in our most vulnerable populations. Historically, clinical trial populations have been rather homogenous, and treatment effect and patient outcomes observed in a trial setting may have limited applicability to the larger ‘real world’ population.

Winner

• Sanofi
  ​

NOMINEES

• Agios Pharmaceuticals
• Arcutis Biotherapeutics
• CISCRP
• Moderna
• Sanofi
  ​

WHO CAN ENTER

To be eligible, the initiatives undertaken must have been activated between August 2021 – January 2023. Entrants must have played a role in the design, launch or execution of the plans, and all joint parties must be disclosed in the application.

This Award will recognize an early phase research project that met or surpassed its objectives on a range of key performance indicators.

Winner

• Avidity Biosciences
  
  

NOMINEES

• Avidity Biosciences
• Daiichi Sankyo
• Enalare
• Gritstone Bio
• Kura Oncology
• Rani Therapeutics and Nucleus Network
  
  

WHO CAN ENTER

To be eligible, results for the study or program under nomination must have been released between August 2021 – January 2023. Entrants must have played a role in the early phase research, and all joint parties must be disclosed in the application.

This Award will recognize the clinical research team who have made significant contributions in advancing a new therapy through one or more clinical phases. The judges will be looking to reward the high performing team that has been most successful in reaching its goals, adopted effective working practices, achieved major milestones within expected timelines, and contributed to the advancement of new therapies.

Winner

• George Clinical
  
  

NOMINEES

• Daiichi Sankyo and AstraZeneca
• George Clinical
• Kura Oncology
• PPD, clinical research business of Thermo Fisher Scientific
• Servier Pharmaceuticals
• Tarsus Pharmaceuticals
  
  

WHO CAN ENTER

To be eligible, the core project for the nominated team must be ongoing or completed between August 2021 – January 2023.

This Award will recognize the clinical trial which reported results that had the greatest impact and is expected to lead to an advance in healthcare. The judges will be looking to reward the clinical trial with the largest commercial impact, highest impact on patient population, the greatest disruption in a market, or the advancement of clinical trial design.

Winner

• Tarsus Pharmaceuticals
  
  

NOMINEES

• Daiichi Sankyo and AstraZeneca
• Dr. Ferrer BioPharma
• Tarsus Pharmaceuticals
  
  

WHO CAN ENTER

To be eligible, results for the study under nomination must have been presented in the public domain between August 2021 – January 2023. Entrants must have played a role in the clinical study, and all joint parties must be disclosed in the application.

The attempt to combat rare diseases is a challenging task that exemplifies how the pharmaceutical industry addresses unmet medical needs. This Award will recognize the efforts of an individual, team, or company that demonstrated excellence while developing a drug intended to treat rare diseases. The judges will be looking for a drug development program or trial with the largest potential impact in the rare disease space.

Winner

• Agios Pharmaceuticals
  ​

NOMINEES

• Agios Pharmaceuticals
• Alector
• Alexion
• BridgeBio and Calcilytix Therapeutics
• Inozyme Pharma
• Marinus Pharmaceuticals
• Mirum Pharmaceuticals
  ​

WHO CAN ENTER

To be eligible, drug development activities must have taken place between August 2021 – January 2023. Entrants must have played a role in drug development and/or trial conduct, and all joint parties must be disclosed in the application.

This Award recognizes the promising and disruptive role that digital health technology is currently playing in clinical trials. Technological innovators are discovering novel ways to gather high quality patient data using an array of digital tools. Advances in development of smartphone apps, mobile health devices, and a host of other products are revolutionizing the way patients participate in clinical trials. The judges will be looking for the product that represents the best advance in improving patient data collection and/or the patient experience in clinical trials.

Winner

• TrialWire
  ​

NOMINEES

• Alira Health
• Greenphire with Signant Health
• myMedidata App and Designer by Medidata, a Dassault Systèmes Company
• ProofPilot
• TrialWire
• UBC & Seqster
  ​

WHO CAN ENTER

All recently launched or significantly updated technologies are eligible to enter if they were used in at least one clinical trial between August 2021 – January 2023.

This Award recognizes the vital importance of using the most sophisticated platforms to catalyse and optimize data gathered during clinical trials. Advances in software and applications have a pivotal role to play at all stages of the trial process, assisting Sponsors in effective management of study logistics, monitoring, risk mitigation and timely data collection and analysis. The judges will be Information Classification: Generallooking for the product or suite of products that help study teams better manage and oversee clinical trial activities.

Winner

• TransPerfect Life Sciences
  ​

NOMINEES

• Biofourmis
• Greenphire
• IQVIA’s IRT eCOA solution
• ProofPilot
• Tata Consultancy Services – TCS ADD Platforms
• TransPerfect Life Sciences
• Winterlight Labs
  ​

WHO CAN ENTER

All recently launched or significantly updated technologies are eligible to enter if they were used in at least one clinical trial between August 2021 – January 2023.

This Award will be presented to two or more organizations who have set a new benchmark in partnering through collaborative clinical trial activity that took place in 2021/22. Partnerships could take place between multiple pharmaceutical and/or biotech companies or between a pharmaceutical and/or biotech company and a contract research organization, research institute, non-profit, or cooperative group.

Winner

• Medidata, a Dassault Systèmes Company, and Circuit Clinical
  ​

NOMINEES

• CISCRP and Pitch Black
• Defender Pharmaceuticals and Catalyst Flex
• Enalare and NEMA Research
• Medidata, a Dassault Systèmes Company, and Circuit Clinical
  ​

WHO CAN ENTER

To be eligible, the collaborative clinical trial activity in question must be ongoing or completed between August 2021 – January 2023..

Artificial intelligence (AI) is revolutionizing healthcare and its application in Pharma is gaining momentum. AI technology provides new opportunities to improve drug discovery, clinical development and commercial adoption of new medicines. This Award will recognize the efforts of an individual, team, or company in leveraging artificial intelligence to improve a clinical trial process, or to support the successful execution of a clinical trial.

Winner

• Yseop
  ​

NOMINEES

• CluePoints
• ICON
• Roche and IQVIA NLP
• Tata Consultancy Services - TCS ADD Risk Based Monitoring and Medical Monitoring Platform
• Unlearn
• Yseop
  ​

WHO CAN ENTER

To be eligible, activities must have taken place between August 2021 – January 2023. Entrants must have played a role in the design, implementation or application of the AI tool, and all joint parties must be disclosed in the application.

Clinical trials are high risk, expensive, resource-intense undertakings that present significant challenges to small companies with limited financial and human capital. This award will recognize a start-up pharma/biotech company that has developed creative and innovative approaches to the formidable challenges that clinical trials present to small organizations.

Winner

• Electra Therapeutics
  ​

NOMINEES

• Advantx
• Akadeum Life Sciences
• Biofourmis
• Electra Therapeutics
• Innophore
• VersaTrial
• Veterinary Health Research Centers
  ​

WHO CAN ENTER

Start-up pharma/biotech companies wishing to enter must have designed, delivered and launched the innovation (alone or with a partner), and all parties to any joint development activities must be disclosed in the application.